GGrantIndex
← Search

Open label, phase I/II trial of rituximab for chronic, severe ITP

$11,107M01FY2004RRNIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

View original record on NIH RePORTER →